Cargando…
TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
Malignant melanoma is an aggressive form of cancer, which can be treated with anti-CTLA-4 and anti-PD-1 checkpoint inhibitor antibodies but while anti-CTLA-4 antibodies have clear benefits for some patients with melanoma, productive responses are difficult to predict and often associated with seriou...
Autores principales: | Khanolkar, Rahul C., Zhang, Chu, Al-Fatyan, Farah, Lawson, Linda, Depasquale, Ivan, Meredith, Fiona M., Muller, Frank, Nicolson, Marianne, Dahal, Lekh Nath, Abu-Eid, Rasha, Rajpara, Sanjay, Barker, Robert Norman, Ormerod, Anthony D., Ward, Frank James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767111/ https://www.ncbi.nlm.nih.gov/pubmed/35069536 http://dx.doi.org/10.3389/fimmu.2021.763877 |
Ejemplares similares
-
TGF-β2 mediated secretion of sCTLA-4 from regulatory T cells
por: Khanolkar, R, et al.
Publicado: (2015) -
A Novel Role for the Soluble Isoform of CTLA-4 in Normal, Dysplastic and Neoplastic Oral and Oropharyngeal Epithelia
por: Clare, Prarthna, et al.
Publicado: (2023) -
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
por: Dahal, Lekh N., et al.
Publicado: (2016) -
Investigation of Soluble and Transmembrane CTLA-4 Isoforms in Serum and Microvesicles
por: Esposito, Laura, et al.
Publicado: (2014) -
Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms
por: Berry, Andrew, et al.
Publicado: (2008)